Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from SCRIP

11:43 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "SCRIP" found in our extensive news archives from over 250 global news sources.

More Information about SCRIP on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about SCRIP for you to read. Along with our medical data and news we also list SCRIP Clinical Trials, which are updated daily. BioPortfolio also has a large database of SCRIP Companies for you to search.

Showing News Articles 1–25 of 3,200+ from SCRIP

Tuesday 13th November 2018

INFOGRAPHIC: INFOGRAPHIC: Sweden's Vibrant And Growing Life Sciences Landscape

Sweden's life science industry is a key component of the Scandinavian country's economy. New life science companies emerge there every...   

Monday 12th November 2018

AI-Powered 'Doctor' Adds Fuel To China Digital Health Investment Fire

China’s artificial intelligence-powered healthcare ambition takes a new form, a 24-hour health clinic complete with a medicine dispenser that may...   

Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop

Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on...   

Revised Korean Innovative Drug Pricing System Draws Strong Pharma Objections

Local and multinational pharma associations voice objections to proposed revisions to innovative drug pricing system in South Korea as part...   

Amarin's REDUCE-IT Data For Vascepa May Be Game-Changing, But Not Without Controversy

CVOT results for Amarin's fish-oil pill show an unprecedented reduction in cardiovascular deaths. While questions have been raised about an...   

New Year Present For Takeda As Shire Close Nears?

Takeda is hoping to start 2019 with a bang, saying its huge acquisition of Shire might become a done deal...   

Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment

Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company...    

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV

UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings...   

Moment Of Truth For Pacritinib And Other EU Approval Hopefuls

CTI BioPharma has had a bumpy ride with pacrotinib, its investigational treatment for patients with myelofibrosis who have thrombocytopenia. But...   

AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review

Despite suffering a setback at the hands of NICE, AstraZeneca's ambitious plans for Lynparza have been boosted by the FDA...   

The Meta-Physics Of Meta-Analysis: US FDA’s Curious Framing Of New Safety Guidance

Long delayed guidance on meta-analysis “will assist sponsors of drug and biological products in designing safety meta-analyses of randomized controlled...  

Is Bloom Gone From Rosy ANDA Approvals Figures?

US FDA sets a new monthly record for full approvals, but industry group argues that approvals alone aren't creating more...   

'Teva Has Earned Nothing,' US FDA Tells Court In Battle Over Generic Restasis 180-Day Exclusivity

Court orders agency to provide 48 hours' notice before issuing decision that would allow any manufacturer other than Teva to...   

US FDA Drug Development Tool Qualification Takes Center Stage At December Meeting

Public session to gather input on taxonomy and scientific criteria for qualifying animal models, biomarkers and clinical outcome assessments is...   

Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche

Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive...   

ThermoLife Tries To Flex Litigation Muscle Against Nitrate Marketers In False Advertising Complaints

ThermoLife International files two false advertising complaints alleging competitors also marketing nitrate-based workout products deceive consumers and disparage its business...   

Back In Fashion? Boston’s CBO Talks Turkey On Reinvigorating Pharma’s Unwanted Assets

Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline...    

DATA: Starts & Stops: FDA Approves Medtronic's Plan For 340-Patient Renal Denervation Trial

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial...   

Starts & Stops: FDA Approves Medtronic's Plan For 340-Patient Renal Denervation Trial

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial...   

Cosmetics Weekly Trademark Review: Nov. 7

Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...   

Pipeline Watch: Phase III Print-Outs For Tivozanib, Dulaglutide And VTS-270

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...   

Rebate Reform: Big Changes Are Looming For The US Drug Market

Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system...   

Sunday 11th November 2018

Accera Sees New Potential As It Renames, Expands To Asia To Progress Alzheimer’s Asset

The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia...   

FDA Launches Protocol For Inspections Of Sterile Drug Manufacturing Facilities

US FDA expects the New Inspection Protocol Project (NIPP) it launched Nov. 9 to increase the consistency of its sterile...   

Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel

FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks